This factsheet covers deciphering the immunopeptidome for neoantigen identification including:

• Identification of naturally presented HLA class I- and II-bound peptides from cancerous cells and tissues is crucial to leverage the development of immunoncology-based therapies
• Underlying therapeutic principles can be harnessed to fight infectious diseases
• Evotec’s immunopeptidomics platform enables the unbiased identification of novel immunotherapeutic targets
• Identification of diagnostic and monitoring biomarker signatures in normal and altered cells from cohort studies
• Supports biological insight into the connection between T cells and MHC- presenting cells
• Evotec’s highly optimised experimental strategy in combination with its industry-leading capabilities in high-end quantitative mass spectrometry reaches highest sensitivity required to distinguish disease-specific (neo)antigens from normally presented peptides
• Integrating whole exome sequencing and/or transciptomics data will power neoepitope discovery
• Advanced statistics and bioinformatics for systems-wide data analysis and in-depth data interpretation facilitates peptide prioritisation
• Identification of up to a thousand peptides per sample
• Direct detection of presented peptides in contrast to approaches solely based on computation-intensive in silico predictions
• Validation and highly accurate quantification of individual peptides through targeted mass spectrometry (PRM-MS)